06:18
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
Broadcast Date
Presenter
Lawrence A. Leiter, MD, FRCPC, FACP, FACE, FAHA, FACC
Therapeutic Area
Cardiovascular
Dr. Lawrence Leiter, highlights the dosing regimens, efficacy and safety profiles of evolocumab, alirocumab, and inclisiran, providing insights from more recent clinical trials.
